Abstract
The reactogenicities and immunogenicities of two influenza virus vaccines were compared in a placebo-controlled clinical trial among healthy ambulatory persons > or = 65 years old (mean age, 72 years). Volunteers were assigned randomly to receive 15-, 45-, or 135-micrograms doses of monovalent influenza A/Taiwan (H1N1) hemagglutinin (HA) or subvirion (SV) vaccine intramuscularly or a placebo. Increasing doses of SV vaccine were associated with a higher rate of injection site discomfort (P < 0.05; chi-square test for linear trend), but all doses of both vaccines were well tolerated. Increasing the dose of the HA or the SV vaccine resulted in increasingly higher postimmunization levels of serum hemagglutination inhibition and neutralizing antibody levels (P < 0.001; multiple linear regression). Mean serum antibody titers at 1 month increased two- to threefold with a ninefold increase in dose; the frequencies of fourfold or greater rises in titer likewise increased. An increase in the dose of the HA or the SV vaccine also resulted in increased frequencies of rises in immunoglobulin A or G antibody titers in nasal wash specimens. The frequencies increased approximately twofold for each vaccine with a ninefold increase in the dose. These data suggest that increasing the HA vaccine dose is a promising approach to the development of improved influenza virus vaccines for use in elderly people.
Full Text
The Full Text of this article is available as a PDF (188.0 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Frank A. L., Puck J., Hughes B. J., Cate T. R. Microneutralization test for influenza A and B and parainfluenza 1 and 2 viruses that uses continuous cell lines and fresh serum enhancement. J Clin Microbiol. 1980 Sep;12(3):426–432. doi: 10.1128/jcm.12.3.426-432.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Gross P. A., Quinnan G. V., Jr, Weksler M. E., Gaerlan P. F., Denning C. R. Immunization of elderly people with high doses of influenza vaccine. J Am Geriatr Soc. 1988 Mar;36(3):209–212. doi: 10.1111/j.1532-5415.1988.tb01802.x. [DOI] [PubMed] [Google Scholar]
- Keitel W. A., Couch R. B., Cate T. R., Hess K. R., Baxter B., Quarles J. M., Atmar R. L., Six H. R. High doses of purified influenza A virus hemagglutinin significantly augment serum and nasal secretion antibody responses in healthy young adults. J Clin Microbiol. 1994 Oct;32(10):2468–2473. doi: 10.1128/jcm.32.10.2468-2473.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Keitel W. A., Couch R. B., Cate T. R., Six H. R., Baxter B. D. Cold recombinant influenza B/Texas/1/84 vaccine virus (CRB 87): attenuation, immunogenicity, and efficacy against homotypic challenge. J Infect Dis. 1990 Jan;161(1):22–26. doi: 10.1093/infdis/161.1.22. [DOI] [PubMed] [Google Scholar]
- Mostow S. R., Schoenbaum S. C., Dowdle W. R., Coleman M. T., Kaye H. S., Hierholzer J. C. Studies on inactivated influenza vaccines. II. Effect of increasing dosage on antibody response and adverse reactions in man. Am J Epidemiol. 1970 Oct;92(4):248–256. doi: 10.1093/oxfordjournals.aje.a121204. [DOI] [PubMed] [Google Scholar]
- Palache A. M., Beyer W. E., Sprenger M. J., Masurel N., de Jonge S., Vardy A., Charpentier B., Noury J., van Beek W. C., Borst R. J. Antibody response after influenza immunization with various vaccine doses: a double-blind, placebo-controlled, multi-centre, dose-response study in elderly nursing-home residents and young volunteers. Vaccine. 1993;11(1):3–9. doi: 10.1016/0264-410x(93)90333-s. [DOI] [PubMed] [Google Scholar]
- Powers D. C., Sears S. D., Murphy B. R., Thumar B., Clements M. L. Systemic and local antibody responses in elderly subjects given live or inactivated influenza A virus vaccines. J Clin Microbiol. 1989 Dec;27(12):2666–2671. doi: 10.1128/jcm.27.12.2666-2671.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Powers D. C., Smith G. E., Anderson E. L., Kennedy D. J., Hackett C. S., Wilkinson B. E., Volvovitz F., Belshe R. B., Treanor J. J. Influenza A virus vaccines containing purified recombinant H3 hemagglutinin are well tolerated and induce protective immune responses in healthy adults. J Infect Dis. 1995 Jun;171(6):1595–1599. doi: 10.1093/infdis/171.6.1595. [DOI] [PubMed] [Google Scholar]
- Ruben F. L., Jackson G. G. A new subunit influenza vaccine: acceptability compared with standard vaccines and effect of dose on antigenicity. J Infect Dis. 1972 Jun;125(6):656–664. doi: 10.1093/infdis/125.6.656. [DOI] [PubMed] [Google Scholar]